Combination of estramustine, paclitaxel, and tegafur-uracil (ETU) in patients with metastatic hormone-refractory prostate cancer (mHRPC): Efficacy and safety results of a multicenter phase II study

被引：0
|
作者：
Fitoussi, O.
Guichard, F.
Hirt, S.
Dohollou, N.
Bureau, C.
Auduhy, F.
Guichard, P.
机构：
[1] Polyclin Bordeaux N Aquitaine, Bordeaux, France
[2] Merck Lipha Sante, Lyon, France
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2008年 / 26卷 / 15期
关键词：
D O I：
10.1200/jco.2008.26.15_suppl.16027
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
16027
引用
收藏
页数：1
相关论文
共 50 条
  • [11] Safety and efficacy of docetaxel, estramustine phosphate and hydrocortisone in hormone-refractory prostate cancer patients
    Nakagami, Yoshihiro
    Ohori, Makoto
    Sakamoto, Noboru
    Koga, Shoji
    Hamada, Riu
    Hatano, Tadashi
    Tachibana, Masaaki
    INTERNATIONAL JOURNAL OF UROLOGY, 2010, 17 (07) : 629 - 634
  • [12] Phase II study of estramustine and vinorelbine in hormone-refractory prostate carcinoma patients
    Carles, Joan
    Domenech, Montserrat
    Gelabert-Mas, Antonio
    Nogue, Miquel
    Tabernero, Josep M.
    Arcusa, Angeles
    Guasch, Inmaculada
    Miguel, Ana
    Ballesteros, Juan J.
    Fabregat, Xavier
    Acta Oncologica, 37 (02): : 187 - 191
  • [13] Phase II study of estramustine and vinorelbine in hormone-refractory prostate carcinoma patients
    Carles, J
    Domenech, M
    Gelabert-Mas, A
    Nogue, M
    Tabernero, JM
    Arcusa, A
    Guasch, I
    Miguel, A
    Ballesteros, JJ
    Fabregat, X
    ACTA ONCOLOGICA, 1998, 37 (02) : 187 - 191
  • [14] Phase II trial of oral uracil/tegafur plus leucovorin in patients with hormone-refractory prostate carcinoma
    Bhandari, MS
    Pienta, KJ
    Fardig, J
    Olson, K
    Smith, DC
    CANCER, 2006, 106 (08) : 1715 - 1721
  • [15] Combination chemotherapy with weekly paclitaxel or docetaxel, carboplatin, and estramustine for hormone-refractory prostate cancer
    Yasufuku, Tomihiko
    Shigemura, Katsumi
    Matsumoto, Osamu
    Arakawa, Soichi
    Fujisawa, Masato
    JOURNAL OF INFECTION AND CHEMOTHERAPY, 2010, 16 (03) : 200 - 205
  • [16] Phase II trial of 96-hour paclitaxel plus oral estramustine phosphate in metastatic hormone-refractory prostate cancer
    Hudes, GR
    Nathan, F
    Khater, C
    Haas, N
    Cornfield, M
    Giantonio, B
    Greenberg, R
    Gomella, L
    Litwin, S
    Ross, E
    Roethke, S
    McAleer, C
    JOURNAL OF CLINICAL ONCOLOGY, 1997, 15 (09) : 3156 - 3163
  • [17] The use of paclitaxel, estramustine, and etoposide in the treatment of patients with hormone-refractory prostate cancer
    Pienta, KJ
    Smith, DC
    SEMINARS IN ONCOLOGY, 1999, 26 (06) : 51 - 51
  • [18] Phase II trial of oral estramustine, oral etoposide, and intravenous paclitaxel in hormone-refractory prostate cancer
    Smith, DC
    Esper, P
    Strawderman, M
    Redman, B
    Pienta, KJ
    JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (06) : 1664 - 1671
  • [19] Weekly administration of docetaxel in combination with estramustine and celecoxib in patients with advanced hormone-refractory prostate cancer: final results from a phase II study
    J Carles
    A Font
    B Mellado
    M Domenech
    E Gallardo
    J L González-Larriba
    G Catalan
    J Alfaro
    A Gonzalez del Alba
    M Nogué
    P Lianes
    J M Tello
    British Journal of Cancer, 2007, 97 : 1206 - 1210
  • [20] Phase II study of estramustine, oral etoposide, and vinorelbine in hormone-refractory prostate cancer
    Colleoni, M
    Graiff, C
    Vicario, G
    Nelli, P
    Sgarbossa, G
    Pancheri, F
    Manente, P
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 1997, 20 (04): : 383 - 386
12345